Stephan Grupp MD PhD
2 clinical trials · 2 recruiting · OTHER
Trials by Stephan Grupp MD PhD
RECRUITINGPhase 1NCT06934382
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
This will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogeneic anti-CD7 CART therapy.
Sponsor: Stephan Grupp MD PhDEnrolling: 331 location
T-Cell Acute Lymphoblastic Leukemia/Lymphoma
RECRUITINGPhase 2NCT05029336
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
A subset of autoimmune diseases (ADs) in children and young adults are life-threatening and unresponsive to conventional treatments. In these patients, the delivery of high dose...
Sponsor: Stephan Grupp MD PhDEnrolling: 201 location
Systemic Lupus ErythematosusSystemic Sclerosis